Genmab takes its Profound buy into endometrial
The Rainfol-03 trial, in second-line endometrial cancer, builds on recent early data.
Zymeworks restocks its clinical pipeline
After ZW171's exit, ZW251 enters the clinic.
Merus's next shot is colorectal cancer
Petosemtamab's phase 2 data in this setting should come by the year end.
AbbVie broadens its telisotuzumab conjugate push
A new phase 2/3 will enrol a broad second-line EGFR-mutant NSCLC population.
J&J goes straight into phase 3 in prostate
The company is to test its KLK2-targeting pasritamig in a late-line setting.
AbbVie makes a bigger bet on SEZ6
But first it will need to identify the optimal dose in first-line small-cell lung cancer.
BioNTech's take on iza-bren enters the clinic
The latest projects newly into human trials include BNT3212.
Survival questions delay bemarituzumab
Ocular toxicities could be the reason.
